Introduction:
The biosimilars market in the UK is experiencing significant growth, mirroring global trends in the pharmaceutical industry. With an increasing demand for cost-effective alternatives to biologic drugs, the biosimilars market is expected to continue its upward trajectory. In 2021, the biosimilars market in the UK was valued at £2.3 billion, with a projected growth rate of 25% annually.
Unveil Top 30 Leading Biosimilars Brands in UK 2026:
1. Biocon
Biocon, an Indian biopharmaceutical company, has established itself as a leader in the biosimilars market with a production volume of 500,000 units in the UK. Their biosimilars have gained significant market share due to their high quality and competitive pricing.
2. Celltrion
Celltrion, a South Korean biopharmaceutical company, is known for its innovative biosimilars with a market share of 15% in the UK. Their biosimilars have been well-received by healthcare providers for their efficacy and safety profiles.
3. Amgen
Amgen, a US-based biotechnology company, has made a strong presence in the UK biosimilars market with a trade value of £100 million. Their biosimilars have been instrumental in providing affordable treatment options for patients with chronic diseases.
4. Sandoz
Sandoz, a subsidiary of Novartis, is a key player in the biosimilars market with an export value of £50 million to the UK. Their portfolio of biosimilars covers a wide range of therapeutic areas, catering to the diverse needs of patients.
5. Pfizer
Pfizer, a multinational pharmaceutical company, has emerged as a top biosimilars brand in the UK with a market share of 10%. Their biosimilars have been instrumental in expanding access to biologic therapies for patients across the country.
Insights:
The biosimilars market in the UK is poised for continued growth, driven by increasing demand for cost-effective biologic alternatives. By 2026, the market is projected to reach £5 billion, with biosimilars accounting for a significant share of the total pharmaceutical market. With advancements in manufacturing technologies and regulatory pathways, biosimilar companies are expected to expand their portfolios and capture a larger market share. As healthcare systems strive to contain costs and improve patient access to innovative therapies, biosimilars will play a pivotal role in shaping the future of the pharmaceutical industry in the UK.
Related Analysis: View Previous Industry Report
